Infosys Limited vs Moderna, Inc. — how do they compare? Infosys Limited trades at $12.2 (market cap $50.55B), while Moderna, Inc. trades at $63.73 (market cap $24.18B). The key difference: Infosys Limited is far larger — about 2.1× Moderna, Inc.'s market cap, and Infosys Limited pays a 4.16% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| INFY | MRNA | |
|---|---|---|
Market Cap | $50.55B | $24.18B |
Sector | Technology | Health |
52-Week High | $20.22 | $81.80 |
52-Week Low | $10.49 | $22.36 |
Enterprise Value | $48.30B | $20.33B |
Dividend Yield | 4.16% | — |
Signals from Pluang's Aura AI — not financial advice
INFY trades at $12.17, down 3.11% today, with mixed technical signals: a bullish moving average trend but overbought RSI levels. The company reported a Q2 2026 EPS miss but beat in prior quarters, maintaining strong profitability with a 16.37% net margin. Recent news highlights AI collaborations and a CEO transition, while institutional activity shows both buying and selling.
Outlook is cautious due to near-term revenue softness and lowered growth guidance, though solid cash flow and margins provide support. Risks include competitive pressures and macroeconomic headwinds. Analysts are mixed with a consensus price target of $11.05, suggesting limited upside from current levels.
Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.
The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.
Trailing returns across standard periods
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →